TruScreen (ASX: TRU) has been named in the ‘6 Top Women’s Health Startups Impacting Healthcare’ by StartUs Insights, an Austrian based data science company.
In a report titled StartUs Insights, the company used AI analytics to evaluate 580 global women’s healthcare companies, ranking TruScreen in its Top 6 Picks.
The report commented that “Cervical cancer is a major cause of female mortality worldwide, with a bigger death toll in the populations that lack screening programs. Screening methods that don’t require lab facilities for cervical cancer diagnostics can solve the accessibility challenges in developing countries as they are an alternative to traditional Pap smear tests.
TruScreen develops a screening device that detects precancerous changes through optical and electrical measurements of cervical tissue. In a number ofstudies, TruScreen proved to be of equal sensitivity compared to Pap tests. TruScreen can be effectively used with minimal training of medical or paramedical staff and doesn’t require the infrastructure and resource costs associated with cytology- based screening.”
“The ranking of TruScreen as a global top six women’s healthcare company is a testament of TruScreen’s technology to lower the high global mortality rate of women from Cervical Cancer,” TruScreen CEO, Martin Dillon, said.
“TruScreen is pleased to be recognised as a scaled up startup company with technology data sets that are robust and supported with global clinical trials. And that our technology ranks above 574 other global women’s healthcare companies evaluated in 2024 for this report.”
TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardised Prevent and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam’s public and private healthcare sectors.
